Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapine

Eur Arch Psychiatry Clin Neurosci. 2019 Dec;269(8):931-940. doi: 10.1007/s00406-018-0965-4. Epub 2018 Dec 11.

Abstract

Obsessive-compulsive symptoms (OCS) in patients with schizophrenia are a common co-occurring condition, often associated with additional impairments. A subgroup of these patients develops OCS during treatment with second-generation antipsychotics (SGAs), most importantly clozapine and olanzapine. So far, little is known about possible neural mechanism of these SGAs, which seem to aggravate or induce OCS. To investigate the role of SGA treatment on neural activation and connectivity during emotional processing, patients were stratified according to their monotherapy into two groups (group I: clozapine or olanzapine, n = 20; group II: amisulpride or aripiprazole, n = 20). We used an fMRI approach, applying an implicit emotion recognition task. Group comparisons showed significantly higher frequency and severity of comorbid OCS in group I than group II. Task specific activation was attenuated in group I in the left amygdala. Furthermore, functional connectivity from left amygdala to right ventral striatum was reduced in group I. Reduced amygdala activation was associated with OCS severity. Recent literature suggests an involvement of an amygdala-cortico-striatal network in the pathogenesis of obsessive-compulsive disorder. The observed differential activation and connectivity pattern of the amygdala might thus indicate a neural mechanism for the development of SGA-associated OCS in patients with schizophrenia. Further neurobiological research and interventional studies are needed for causal inferences.

Keywords: Amygdala; Antipsychotic; Obsessive–compulsive; Schizophrenia; fMRI.

MeSH terms

  • Adult
  • Amygdala / diagnostic imaging
  • Amygdala / drug effects*
  • Amygdala / pathology
  • Amygdala / physiopathology
  • Antipsychotic Agents / therapeutic use*
  • Carrier Proteins
  • Clozapine / therapeutic use*
  • Female
  • Functional Neuroimaging
  • Humans
  • Male
  • Neural Pathways / drug effects
  • Neural Pathways / pathology
  • Neural Pathways / physiopathology
  • Olanzapine / therapeutic use*
  • Saccharomyces cerevisiae Proteins
  • Schizophrenia / diagnostic imaging
  • Schizophrenia / drug therapy*
  • Schizophrenia / pathology
  • Schizophrenia / physiopathology

Substances

  • Antipsychotic Agents
  • Carrier Proteins
  • Saccharomyces cerevisiae Proteins
  • YKL069W protein, S cerevisiae
  • Clozapine
  • Olanzapine